We are live on
!
Find out more
IC
Ikarian Capital Portfolio holdings
AUM
$1.23B
1-Year Est. Return
600.17%
This Fund
S&P 500
This Quarter
Est. Return
+39.15%
1 Year Est. Return
+600.17%
3 Year Est. Return
+5,763.15%
5 Year Est. Return
+15,527.6%
10 Year Est. Return
–
AUM
$831M
AUM Growth
+$203M
(+32%)
Cap. Flow
-$333M
Cap. Flow
% of AUM
-40.1%
Top 10 Holdings %
Top 10 Hldgs %
41.06%
Holding
181
New
59
Increased
25
Reduced
46
Closed
41
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Rocket Pharmaceuticals
RCKT
|
+$11.9M |
| 2 |
AKRO
Akero Therapeutics
AKRO
|
+$9.31M |
| 3 |
Tarsus Pharmaceuticals
TARS
|
+$9.18M |
| 4 |
CPRX
Catalyst Pharmaceutical
CPRX
|
+$6.77M |
| 5 |
Immunovant
IMVT
|
+$6.73M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Merck
MRK
|
+$11.5M |
| 2 |
Insmed
INSM
|
+$7.55M |
| 3 |
IDEAYA Biosciences
IDYA
|
+$6.95M |
| 4 |
Biohaven
BHVN
|
+$6.68M |
| 5 |
Biomea Fusion
BMEA
|
+$6.06M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 31.68% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
1
PUT
State Street SPDR S&P 500 ETF Trust
SPY
$778B
| $64.1M | 7.71% |
+1,500
| New | +$667K |
|
2
PUT
Sarepta Therapeutics
SRPT
$1.65B
| $44.5M | 5.36% |
3,673
-118,427
| -97% | -$13.4M |
|
3
PUT
Invesco QQQ Trust
QQQ
$456B
| $43M | 5.17% |
+1,200
| New | +$445K |
|
4
PUT
State Street SPDR S&P Biotech ETF
XBI
$10.1B
| $36.5M | 4.39% |
+5,000
| New | +$399K |
|
|
SLRN
5
DELISTED
ACELYRIN
SLRN
| $29.7M | 3.57% |
2,918,426
| – | – |
|
|
6
CALL
Immunovant
IMVT
$8B
| $27.8M | 3.34% |
7,230
-318,970
| -98% | -$7.21M |
|
|
7
CALL
Sarepta Therapeutics
SRPT
$1.65B
| $25.7M | 3.1% |
2,123
-19,977
| -90% | -$2.26M |
|
8
PUT
Moderna
MRNA
$21.5B
| $25.2M | 3.04% |
+2,443
| New | +$273K |
|
9
Crinetics Pharmaceuticals
CRNX
$8.87B
| $23.6M | 2.84% |
792,920
+317,920
| +67% | +$6.55M |
|
|
10
PUT
Immunovant
IMVT
$8B
| $21.2M | 2.56% |
5,534
-70,466
| -93% | -$1.59M |
|
11
CALL
AbbVie
ABBV
$457B
| $19.8M | 2.38% |
+1,325
| New | +$195K |
|
|
SLNO
12
DELISTED
Soleno Therapeutics
SLNO
| $15.8M | 1.91% |
+536,720
| New | +$3.25M |
|
|
AKRO
13
PUT
DELISTED
Akero Therapeutics
AKRO
| $15.4M | 1.86% |
+3,049
| New | +$142K |
|
|
14
PUT
Crinetics Pharmaceuticals
CRNX
$8.87B
| $13.5M | 1.63% |
+4,543
| New | +$93.6K |
|
|
15
Rocket Pharmaceuticals
RCKT
$348M
| $13.4M | 1.61% |
+654,726
| New | +$11.9M |
|
|
NUVL
16
DELISTED
Nuvalent
NUVL
| $12.8M | 1.54% |
278,034
+5,282
| +2% | +$234K |
|
17
BridgeBio Pharma
BBIO
$16.4B
| $12.5M | 1.5% |
473,126
+43,440
| +10% | +$1.23M |
|
|
18
CALL
Crinetics Pharmaceuticals
CRNX
$8.87B
| $12.1M | 1.45% |
+4,054
| New | +$83.5K |
|
|
19
Immunovant
IMVT
$8B
| $11.4M | 1.38% |
+297,794
| New | +$6.73M |
|
|
NUVL
20
CALL
DELISTED
Nuvalent
NUVL
| $11M | 1.32% |
2,395
-2,005
| -46% | -$89K |
|
21
PUT
Syndax Pharmaceuticals
SNDX
$1.84B
| $10.9M | 1.31% |
+7,500
| New | +$142K |
|
|
AKRO
22
DELISTED
Akero Therapeutics
AKRO
| $10.1M | 1.22% |
+200,000
| New | +$9.31M |
|
|
AKRO
23
CALL
DELISTED
Akero Therapeutics
AKRO
| $10.1M | 1.21% |
+1,989
| New | +$92.6K |
|
24
PUT
Krystal Biotech
KRYS
$9.79B
| $9.8M | 1.18% |
845
-9,455
| -92% | -$1.15M |
|
25
PUT
Replimune Group
REPL
$841M
| $9.3M | 1.12% |
5,438
-342,762
| -98% | -$6.73M |
|
Similar funds
FLII
NHAS
HCA
GX
WCM
MP
IA
IB
Ikarian Capital's Q3 2023 Portfolio in Review
As of Q3 2023, Ikarian Capital held 181 positions worth $831M, up 32% from $628M the previous quarter. Its ten largest holdings account for 41% of the portfolio.
Ikarian Capital withdrew a net $333M in Q3 2023, closing 41 positions and reducing 46 holdings. Its most notable exit was Merck, an estimated $11.5M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 32% of assets, down from 44% a quarter earlier.
Against the trend, Ikarian Capital opened a new position in Rocket Pharmaceuticals worth $13.4M.
- Ikarian Capital's largest Q3 2023 buy was Rocket Pharmaceuticals: 654,726 shares worth $13.4M.
- Ikarian Capital added most to Crinetics Pharmaceuticals in Q3 2023, an estimated $6.55M increase.
- Ikarian Capital's biggest Q3 2023 reduction was Insmed, cutting an estimated $7.55M.
- Ikarian Capital fully exited Merck in Q3 2023, selling an estimated $11.5M.
- Ikarian Capital's ten largest holdings make up 41% of its $831M portfolio in Q3 2023.
- Ikarian Capital opened 59 new positions and closed 41 in Q3 2023.
- Ikarian Capital's portfolio value rose 32% quarter-over-quarter to $831M.
Based on Ikarian Capital's 13F filing for Q3 2023, filed 14 Nov 2023.